,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1471,2,1,,50112789,5517,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
1,1490,2,1,,50112789,5517,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
2,1688,1,1,,50112789,5517,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
3,1766,1,1,,50112789,5517,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
4,1766,1,1,,50112789,5517,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
5,1768,1,1,,50112789,5517,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
6,1768,1,1,,50112789,5517,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
7,2528,1,2,,50112789,5517,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
8,2546,1,1,,50112789,5517,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
9,2551,1,1,,50112789,5517,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
10,2662,2,1,,50112789,5517,Inconclusive,56550039.0,4297.0,14.1254,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
11,10501,7,2,,103178054,5517,Unspecified,,,,,AUC in mice,Other,1738144.0,
12,13864,7,2,,103178054,5517,Unspecified,,,,,Cmax in mouse plasma,Other,1738144.0,
13,20932,7,1,,103178054,5517,Unspecified,,,,,Compound was evaluated for the solubility in Ringer's buffer solution,Other,2840501.0,
14,21154,4,4,,103178054,5517,Unspecified,,,,,% dose recovered in mouse urine,Other,1738144.0,
15,21753,5,2,,103178054,5517,Unspecified,,,,,Solubility was measured at PH - 7.2 buffer,Other,1738144.0,
16,23542,6,2,,103178054,5517,Unspecified,,,,,Solubility (in 0.1 N HCl),Other,1366133.0,
17,23544,6,2,,103178054,5517,Unspecified,,,,,Solubility (at pH 4),Other,1366133.0,
18,23546,6,2,,103178054,5517,Unspecified,,,,,Aqueous solubility,Other,1366133.0,
19,23549,6,2,,103178054,5517,Unspecified,,,,,Solubility (at pH 7.4),Other,1366133.0,
20,24221,3,3,,103178054,5517,Unspecified,,,,,Partition coefficient (logP),Other,2840501.0,
21,24564,6,2,,103178054,5517,Unspecified,,,,,t1/2 in mouse plasma,Other,1738144.0,
22,26270,3,4,,103178054,5517,Unspecified,,,,,Partition coefficient (logD),Other,1738144.0,
23,30272,7,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Acinetobacter CMX 669,Other,2840501.0,
24,30276,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Acinetobacter CMX 669 using brain-heart infusion agar,Other,1573632.0,
25,30399,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Acinetobacter calcoaceticus No.4,Other,9873632.0,
26,30422,6,3,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against Acinetobacter species CMX669,Other,3783594.0,
27,40338,6,2,,103178054,5517,Unspecified,,,,,In vitro for antibacterial activity against Bacillus fragilis.,Other,1738144.0,
28,43924,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Burkholderia cepacia 23,Other,9873632.0,
29,51918,7,2,,103178054,5517,Unspecified,,,,,Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity),Other,1469702.0,
30,52937,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Citrobacter freundii KP-29,Other,9873632.0,
31,52938,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Citrobacter freundii No.7,Other,9873632.0,
32,53322,6,4,,103178054,5517,Unspecified,,,,,Inhibition of the gyrase mediated cleavage of supercoiled DNA,Other,8393112.0,
33,64389,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against gram negative Enterobacter cloacae MA 2646.,Other,1366133.0,
34,65233,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against gram negative Escherichia coli Vogel.,Other,1366133.0,
35,65397,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against gram positive Enterococcus faecalis MGH-2.,Other,1366133.0,
36,66105,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Enterococcus faecium ATCC 8043 using brain-heart infusion agar,Other,1573632.0,
37,67215,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram positive Enterococcus faecalis 1373,Other,9873632.0,
38,67225,6,2,,103178054,5517,Unspecified,,,,,In vitro for antibacterial activity against Enterococcus faecalis,Other,1738144.0,
39,67685,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against Enterobacter aerogenes ATCC 13048,Other,3783594.0,
40,67755,5,3,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration in vitro against Enterococcus faecalis LS-101,Other,,
41,67874,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Enterobacter aerogenes ATCC 13048 using brain-heart infusion agar,Other,1573632.0,
42,67884,7,2,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration was evaluated in vitro against Enterococcus faecalis MGH-2,Other,8385225.0,
43,68019,7,2,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration in vitro against Enterobacter cloacae MA 2646,Other,8385225.0,
44,68172,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Enterobacter cloacae Nek39,Other,9873632.0,
45,68179,6,2,,103178054,5517,Unspecified,,,,,In vitro for antibacterial activity against Enterobacter cloacae,Other,1738144.0,
46,68978,6,2,,103178054,5517,Unspecified,,,,,Supercoiling inhibition assay using purified DNA gyrase isolated from Escherichia coli H560,Other,2840501.0,
47,69639,6,2,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration against Escherichia coli,Other,10737746.0,
48,69641,5,3,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration in vitro against Escherichia coli NIHJ JC-2,Other,,
49,69759,7,2,,103178054,5517,Unspecified,,,,,Antibacterial activity in vitro against Escherichia coli Vogel,Other,8385225.0,
50,70282,8,1,,103178054,5517,Unspecified,,,,,Antibacterial activity against Escherichia coli Vogel after oral administration in mouse,Other,8385225.0,
51,70283,4,3,,103178054,5517,Unspecified,,,,,Antibacterial activity against Escherichia coli Vogel after subcutaneous administration in mouse,Other,8385225.0,
52,70418,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against Escherichia coli Juhl,Other,3783594.0,
53,70426,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Escherichia coli CSH2/RE45,Other,9873632.0,
54,70427,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Escherichia coli CSH2/RK1,Other,9873632.0,
55,70428,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Escherichia coli ML4707,Other,9873632.0,
56,70429,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Escherichia coli NIHJ JC-2,Other,9873632.0,
57,70583,6,2,,103178054,5517,Unspecified,,,,,In vitro for antibacterial activity against Escherichia coli,Other,1738144.0,
58,70612,3,3,,103178054,5517,Unspecified,,,,,Compound was tested for acute toxicity against Escherichia coli A 15119 after oral administration of drug in mice,Other,1738144.0,
59,70753,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Escherichia coli Juhl,Other,2840501.0,
60,70772,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Escherichia coli Juhl using brain-heart infusion agar,Other,1573632.0,
61,74698,5,1,,103178054,5517,Unspecified,,,,,Tested for in vitro antibacterial activity against Gram (+) bacteria,Other,12723953.0,
62,74699,5,1,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against Gram (-) bacteria,Other,12723953.0,
63,74727,7,2,,103178054,5517,Unspecified,,,,,Antibacterial activity against five Gram-negative bacteria,Other,1469702.0,
64,74728,6,2,,103178054,5517,Unspecified,,,,,Geometric mean of MIC was determined in vitro against gram-negative strains using standard microtitration techniques,Other,8393112.0,
65,74853,7,3,,103178054,5517,Unspecified,,,,,Antibacterial activity against five Gram-positive bacteria targeting topoisomerase II (DNA gyrase B GyrB),Other,1469702.0,
66,74854,6,2,,103178054,5517,Unspecified,,,,,Geometric mean of MIC was determined in vitro against gram-positive strains using standard microtitration techniques,Other,8393112.0,
67,87939,8,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against growth of Helicobacter pylori ATCC 43504.,Other,9873510.0,
68,94147,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against gram negative Klebsiella pneumoniae MGH-2.,Other,1366133.0,
69,94220,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Klebsiella pneumoniae 8045 using brain-heart infusion agar,Other,1573632.0,
70,95532,6,2,,103178054,5517,Unspecified,,,,,In vitro for antibacterial activity against Klebsiella pneumoniae,Other,1738144.0,
71,95735,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Klebsiella oxytoca GN 10650,Other,9873632.0,
72,95881,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against Klebsiella pneumoniae 8045,Other,3783594.0,
73,96058,7,2,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration was evaluated in vitro against Klebsiella pneumoniae MGH2,Other,8385225.0,
74,96098,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Klebsiella pneumoniae KC-1,Other,9873632.0,
75,96099,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Klebsiella pneumoniae No.42,Other,9873632.0,
76,96242,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Klebsiella pneumoniae 8045,Other,2840501.0,
77,113337,6,2,,103178054,5517,Unspecified,,,,,In vivo dose(po) inhibiting systemic infections caused by Escherichia coli Juhl in mice.,Other,3783594.0,
78,113339,6,2,,103178054,5517,Unspecified,,,,,In vivo dose(po) inhibiting systemic infections caused by Pseudomonas aeruginosa 5007 in mice.,Other,3783594.0,
79,113341,6,2,,103178054,5517,Unspecified,,,,,In vivo dose(po) inhibiting systemic infections caused by Staphylococcus aureus NCTC 10649 in mice.,Other,3783594.0,
80,113343,6,2,,103178054,5517,Unspecified,,,,,In vivo dose(sc) inhibiting systemic infections caused by Escherichia coli Juhl in mice.,Other,3783594.0,
81,113345,6,2,,103178054,5517,Unspecified,,,,,In vivo dose(sc) inhibiting systemic infections caused by Pseudomonas aeruginosa 5007 in mice.,Other,3783594.0,
82,113347,6,2,,103178054,5517,Unspecified,,,,,In vivo dose(sc) inhibiting systemic infections caused by Staphylococcus aureus NCTC 10649 in mice.,Other,3783594.0,
83,115937,6,2,,103178054,5517,Unspecified,,,,,In vivo antibacterial activity against systemic infection caused by Escherichia coli juhl in mice.,Other,3783594.0,
84,115940,6,2,,103178054,5517,Unspecified,,,,,In vivo antibacterial activity against systemic infection caused by Pseudomonas aeruginosa 5007 in mice.,Other,3783594.0,
85,115942,6,2,,103178054,5517,Unspecified,,,,,In vivo antibacterial activity against systemic infection caused by Staphylococcus aureus NCTC 10649 in mice.,Other,3783594.0,
86,117682,3,3,,103178054,5517,Unspecified,,,,,"Protective dose in vivo was determined in acute, lethal systemic infections in female Charles River CD-1 mice against Escherichia coli Vogel",Other,8393112.0,
87,117684,3,3,,103178054,5517,Unspecified,,,,,"Protective dose in vivo was determined in acute, lethal systemic infections in female Charles River CD-1 mice against Streptococcus pyogenes C-203",Other,8393112.0,
88,125255,6,2,,103178054,5517,Unspecified,,,,,In vitro for antibacterial activity against Morganella morganii,Other,1738144.0,
89,125506,4,3,,103178054,5517,Unspecified,,,,,The ratio of the number of Mongolian gerbils in which Helicobacter pylori was not detected to that of Mongolian gerbils tested (percent) was represented as clearance rate,Other,9873510.0,
90,128916,5,1,,103178054,5517,Unspecified,,,,,Blood level was evaluated by a disk agar diffusion assay at 1.0 hr when administered at a peroral dose of 100 mg/kg,Other,2840501.0,
91,128920,5,1,,103178054,5517,Unspecified,,,,,Blood level was evaluated by a disk agar diffusion assay at 2.0 hr when administered at a peroral dose of 100 mg/kg,Other,2840501.0,
92,128927,5,1,,103178054,5517,Unspecified,,,,,Blood level was evaluated by a disk agar diffusion assay at 3.0 hh when administered at a peroral dose of 100 mg/kg,Other,2840501.0,
93,128931,5,1,,103178054,5517,Unspecified,,,,,Blood level was evaluated by a disk agar diffusion assay at 6.0 hr when administered at a peroral dose of 100 mg/kg,Other,2840501.0,
94,130079,4,3,,103178054,5517,Unspecified,,,,,Compounds were evaluated for phototoxicity no-effect dose in mouse,Other,8385225.0,
95,133960,3,3,,103178054,5517,Unspecified,,,,,In vivo potency against acute systemic infection in mouse caused by Escherichia coli Vogel on oral administration by gavage.,Other,1366133.0,
96,133962,3,3,,103178054,5517,Unspecified,,,,,In vivo potency against acute systemic infection in mouse caused by Escherichia coli vogel on subcutaneous injection.,Other,1366133.0,
97,133965,3,3,,103178054,5517,Unspecified,,,,,In vivo potency against acute systemic infection in mouse caused by Pseudomonas aeruginosa UI-18 on oral administration by gavage.,Other,1366133.0,
98,133966,3,3,,103178054,5517,Unspecified,,,,,In vivo potency against acute systemic infection in mouse caused by Pseudomonas aeruginosa. UI-18. on subcutaneous injection.,Other,1366133.0,
99,133968,3,3,,103178054,5517,Unspecified,,,,,In vivo potency against acute systemic infection in mouse caused by Streptococcus pneumoniae SV-1 on oral administration by gavage.,Other,1366133.0,
100,133970,3,3,,103178054,5517,Unspecified,,,,,In vivo potency against acute systemic infection in mouse caused by Streptococcus pneumoniae SV-1 on subcutaneous injection.,Other,1366133.0,
101,133972,3,3,,103178054,5517,Unspecified,,,,,In vivo potency against acute systemic infection in mouse caused by Streptococcus pyogenes C-203 on oral administration by gavage,Other,1366133.0,
102,133974,3,3,,103178054,5517,Unspecified,,,,,In vivo potency against acute systemic infection in mouse caused by Streptococcus pyogenes C-203 on subcutaneous injection,Other,1366133.0,
103,134724,6,2,,103178054,5517,Unspecified,,,,,Lethal dose was determined in OF1-strain female Swiss mice after intra venous administration of the drug,Other,1738144.0,
104,134725,6,2,,103178054,5517,Unspecified,,,,,Lethal dose was determined in OF1-strain female Swiss mice after oral administration of the drug,Other,1738144.0,
105,151528,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against gram negative Pseudomonas aeruginosa UI-18.,Other,1366133.0,
106,152317,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against gram negative Providencia rettgeri M-1771.,Other,1366133.0,
107,162740,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Proteus mirabilis JY-10,Other,9873632.0,
108,162741,6,2,,103178054,5517,Unspecified,,,,,In vitro for antibacterial activity against Proteus mirabilis,Other,1738144.0,
109,163227,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Proteus vulgaris KS-134,Other,9873632.0,
110,163228,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Proteus vulgaris No.33,Other,9873632.0,
111,163733,7,2,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration was evaluated in vitro against Providencia rettgeri M1771,Other,8385225.0,
112,163944,3,3,,103178054,5517,Unspecified,,,,,Compound was tested for acute toxicity against Pseudomonas aeruginosa A 9843 after oral administration of drug in mice,Other,1738144.0,
113,163947,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Pseudomonas aeruginosa A5007 using brain-heart infusion agar,Other,1573632.0,
114,164088,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Pseudomonas aeruginosa K799 / WT using brain-heart infusion agar,Other,1573632.0,
115,164375,7,2,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration was evaluated in vitro against Pseudomonas aeruginosa UI-18,Other,8385225.0,
116,164560,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against Pseudomonas aeruginosa 5007,Other,3783594.0,
117,164561,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against Pseudomonas aeruginosa K799/WT,Other,3783594.0,
118,164565,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa AK109,Other,9873632.0,
119,164701,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa K-13,Other,9873632.0,
120,164702,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa KP-254,Other,9873632.0,
121,164703,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa PAO1,Other,9873632.0,
122,164720,6,2,,103178054,5517,Unspecified,,,,,In vitro for antibacterial activity against Pseudomonas aeruginosa,Other,1738144.0,
123,164885,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Pseudomonas aeruginosa 5007,Other,2840501.0,
124,164886,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Pseudomonas aeruginosa K799/WT,Other,2840501.0,
125,201273,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against gram positive Staphylococcus aureus H-228.,Other,1366133.0,
126,201409,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against gram positive Staphylococcus aureus UC76.,Other,1366133.0,
127,201951,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against gram positive Streptococcus pneumoniae SV-1.,Other,1366133.0,
128,202109,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against gram positive Streptococcus pyogenes C-203.,Other,1366133.0,
129,203284,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Staphylococcus aureus A 5177 using brain-heart infusion agar,Other,1573632.0,
130,203286,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Staphylococcus aureus CMX 553 using brain-heart infusion agar,Other,1573632.0,
131,203290,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Staphylococcus epidermidis 3159 using brain-heart infusion agar,Other,1573632.0,
132,205389,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Serratia marcescens No.16-2,Other,9873632.0,
133,205392,6,2,,103178054,5517,Unspecified,,,,,In vitro for antibacterial activity against Serratia marcescens,Other,1738144.0,
134,205588,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus epidermidis 3519,Other,3783594.0,
135,205650,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram positive Staphylococcus aureus FDA 209P JC-1,Other,9873632.0,
136,205651,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram positive Staphylococcus aureus JS-1,Other,9873632.0,
137,205652,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram positive Staphylococcus aureus KP-90-3,Other,9873632.0,
138,205653,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram positive Staphylococcus aureus smith,Other,9873632.0,
139,205720,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Staphylococcus epidermidis 3519,Other,2840501.0,
140,205821,6,2,,103178054,5517,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus,Other,1738144.0,
141,205845,5,3,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration in vitro against Staphylococcus aureus FDA 209P,Other,,
142,205846,5,3,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration vitro against Staphylococcus aureus No.88,Other,,
143,205982,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Staphylococcus aureus 45,Other,2840501.0,
144,205983,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Staphylococcus aureus A5177,Other,2840501.0,
145,205984,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Staphylococcus aureus ATCC 6538P,Other,2840501.0,
146,205986,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Staphylococcus aureus CMX 686B,Other,2840501.0,
147,206825,7,2,,103178054,5517,Unspecified,,,,,Compound was tested for antibacterial activity against gram positive Staphylococcus pyogenes cook,Other,9873632.0,
148,207045,7,2,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration was evaluated in vitro against Staphylococcus aureus H 228,Other,8385225.0,
149,207046,7,2,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration was evaluated in vitro against Staphylococcus aureus UC 76,Other,8385225.0,
150,207409,3,3,,103178054,5517,Unspecified,,,,,Compound was tested for acute toxicity against Staphylococcus aureus A 15090 after oral administration of drug in mice,Other,1738144.0,
151,207547,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Staphylococcus aureus ATCC 6538P using brain-heart infusion agar,Other,1573632.0,
152,207960,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus aureus ATCC 6538P,Other,3783594.0,
153,207961,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus aureus CMX 686B,Other,3783594.0,
154,208315,5,3,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration in vitro against Streptococcus pneumoniae Type III,Other,,
155,208743,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Streptococcus agalactiae CMX 508,Other,2840501.0,
156,208790,3,3,,103178054,5517,Unspecified,,,,,Compound was tested for acute toxicity against Streptococcus pneumoniae A 9585 after oral administration of drug in mice,Other,1738144.0,
157,208884,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Streptococcus agalactiae CMX 508 using brain-heart infusion agar,Other,1573632.0,
158,208912,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Streptococcus bovis A5169,Other,2840501.0,
159,208922,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Streptococcus bovis A5169 using brain-heart infusion agar,Other,1573632.0,
160,209130,7,2,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration was evaluated in vitro against Streptococcus pyogenes C 203,Other,8385225.0,
161,209298,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against Streptococcus pyogenes 930,Other,3783594.0,
162,209450,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Streptococcus pyogenes 930,Other,2840501.0,
163,209569,6,2,,103178054,5517,Unspecified,,,,,In vitro antibacterial activity against Streptococcus faecium ATCC 8043,Other,3783594.0,
164,209570,6,2,,103178054,5517,Unspecified,,,,,In vitro Minimum inhibitory concentration against Streptococcus faecium ATCC 8043,Other,2840501.0,
165,209727,7,2,,103178054,5517,Unspecified,,,,,Minimum inhibitory concentration was evaluated in vitro against Streptococcus pneumoniae SV-1,Other,8385225.0,
166,210070,8,1,,103178054,5517,Unspecified,,,,,Compounds were evaluated in vivo for antibacterial activity for mouse protection against Streptococcus pyogenes C 203 after oral administration,Other,8385225.0,
167,210071,4,3,,103178054,5517,Unspecified,,,,,Antibacterial activity measured as mouse protection against Streptococcus pyogenes C 203 after subcutaneous administration,Other,8385225.0,
168,210197,6,2,,103178054,5517,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae,Other,1738144.0,
169,210254,6,2,,103178054,5517,Unspecified,,,,,In vitro minimum inhibitory concentration against Streptococcus pyogenes 930 using brain-heart infusion agar,Other,1573632.0,
170,213589,6,1,,103178054,5517,Unspecified,,,,,Clonogenic cytotoxicity against hamster V-79 cells,Other,8385225.0,
171,368418,6,2,,103178054,5517,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Escherichia coli C316 pHPA containing mutated GyrA gene by agar dilution method,Other,17548499.0,
172,368419,6,2,,103178054,5517,Unspecified,,,,,Antimicrobial activity against Escherichia coli KAM32 expressing deltaacrB ydhE hsd gene by agar dilution method,Other,17548499.0,
173,368420,6,2,,103178054,5517,Unspecified,,,,,Antimicrobial activity against Escherichia coli KAM32 pHPA containing mutated GyrA gene by agar dilution method,Other,17548499.0,
174,368421,6,2,,103178054,5517,Unspecified,,,,,Antimicrobial activity against Escherichia coli KAM32 pSTV28 containing chloramphenicol-resistant vector by agar dilution method,Other,17548499.0,
175,368422,6,2,,103178054,5517,Unspecified,,,,,Antimicrobial activity against Escherichia coli KAM32 pSTVqepA containing qepA gene ligated to pSTV28 plasmid by agar dilution method,Other,17548499.0,
176,368423,6,2,,103178054,5517,Unspecified,,,,,Antimicrobial activity against Escherichia coli KAM32 pSTVdeltaqepA containing disrupted qepA gene by agar dilution method,Other,17548499.0,
177,368424,3,3,,103178054,5517,Unspecified,,,,,Ratio of MIC for Escherichia coli KAM32 pSTVqepA mutant to MIC for Escherichia coli KAM32 pSTV28 mutant,Other,17548499.0,
178,436988,5,2,,103178054,5517,Active,,,32.0,IC50,Inhibition of human HeLa cell proliferation,Confirmatory,19595598.0,
179,492961,1,1,,50112789,5517,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
180,504327,1,1,,50112789,5517,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
181,504332,1,1,,50112789,5517,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
182,504749,1,3,,50112789,5517,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
183,504749,1,3,1.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
184,504749,1,3,2.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
185,504749,1,3,3.0,50112789,5517,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
186,504749,1,3,4.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
187,504749,1,3,5.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
188,504749,1,3,6.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
189,504749,1,3,7.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
190,504749,1,3,8.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
191,504749,1,3,9.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
192,504749,1,3,10.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
193,504749,1,3,11.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
194,504749,1,3,12.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
195,504749,1,3,13.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
196,504749,1,3,14.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
197,504749,1,3,15.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
198,504749,1,3,16.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
199,504749,1,3,17.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
200,504749,1,3,18.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
201,504749,1,3,19.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
202,504749,1,3,20.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
203,504749,1,3,21.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
204,504749,1,3,22.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
205,504749,1,3,23.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
206,504749,1,3,24.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
207,504749,1,3,25.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
208,504749,1,3,26.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
209,504749,1,3,27.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
210,504749,1,3,28.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
211,504749,1,3,29.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
212,504749,1,3,30.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
213,504749,1,3,31.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
214,504749,1,3,32.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
215,504749,1,3,33.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
216,504749,1,3,34.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
217,504749,1,3,35.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
218,504749,1,3,36.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
219,504749,1,3,37.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
220,504749,1,3,38.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
221,504749,1,3,39.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
222,504749,1,3,40.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
223,504749,1,3,41.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
224,504749,1,3,42.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
225,504749,1,3,43.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
226,504749,1,3,44.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
227,504749,1,3,45.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
228,504749,1,3,46.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
229,504749,1,3,47.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
230,504749,1,3,48.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
231,504749,1,3,49.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
232,504749,1,3,50.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
233,504749,1,3,51.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
234,504749,1,3,52.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
235,504749,1,3,53.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
236,504749,1,3,54.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
237,504749,1,3,55.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
238,504749,1,3,56.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
239,504749,1,3,57.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
240,504749,1,3,58.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
241,504749,1,3,59.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
242,504749,1,3,60.0,50112789,5517,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
243,504749,1,3,61.0,50112789,5517,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
244,504832,1,1,,50112789,5517,Active,,,3.7933,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
245,504834,1,1,,50112789,5517,Active,,,1.0691,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
246,504847,1,1,,50112789,5517,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
247,504865,1,1,,50112789,5517,Inconclusive,118600387.0,7398.0,63.0957,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
248,588453,1,1,,124893342,5517,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
249,588456,1,1,,124893342,5517,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
250,588579,1,1,,50112789,5517,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
251,588579,1,1,,124893342,5517,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
252,588590,1,1,,124893342,5517,Inconclusive,154350220.0,11201.0,79.4328,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
253,588795,1,1,,124893342,5517,Inconclusive,4758356.0,2237.0,56.2341,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
254,588855,1,1,,124893342,5517,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
255,588856,1,1,,124893342,5517,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
256,602310,1,2,,124893342,5517,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
257,602332,1,1,,50112789,5517,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
258,602332,1,1,,124893342,5517,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
259,624030,1,2,,50112789,5517,Inactive,160794.0,,40.5334,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
260,624031,1,2,,50112789,5517,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
261,624032,1,2,,50112789,5517,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
262,624044,1,2,,50112789,5517,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
263,624170,1,1,,50112789,5517,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
264,624172,1,1,,50112789,5517,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
265,624173,1,3,,50112789,5517,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
266,624178,1,1,,124893342,5517,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
267,624202,1,1,,124893342,5517,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
268,624263,1,1,,124893342,5517,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
269,624263,1,1,,124893342,5517,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
270,624296,1,1,,50112789,5517,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
271,624297,1,1,,50112789,5517,Inconclusive,7705682.0,51053.0,13.3359,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
272,624349,1,2,,92309034,5517,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
273,624414,1,1,,124893342,5517,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
274,625144,5,5,,103178054,5517,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
275,625145,4,7,,103178054,5517,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
276,625146,5,5,,103178054,5517,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
277,625147,4,7,,103178054,5517,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
278,625148,4,7,,103178054,5517,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
279,625149,4,7,,103178054,5517,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
280,625150,5,5,,103178054,5517,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
281,625151,4,7,,103178054,5517,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
282,625152,4,7,,103178054,5517,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
283,625153,4,7,,103178054,5517,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
284,625154,4,7,,103178054,5517,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
285,625155,4,7,,103178054,5517,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
286,625156,1,9,,103178054,5517,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
287,625157,6,2,,103178054,5517,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
288,625158,3,4,,103178054,5517,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
289,625159,5,5,,103178054,5517,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
290,625160,1,9,,103178054,5517,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
291,625161,4,7,,103178054,5517,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
292,625162,4,7,,103178054,5517,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
293,625163,4,7,,103178054,5517,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
294,625164,1,6,,103178054,5517,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
295,625165,3,4,,103178054,5517,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
296,625166,3,4,,103178054,5517,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
297,625167,5,5,,103178054,5517,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
298,625168,4,7,,103178054,5517,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
299,625169,1,6,,103178054,5517,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
300,625170,3,4,,103178054,5517,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
301,625171,4,7,,103178054,5517,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
302,625172,4,7,,103178054,5517,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
303,625173,5,5,,103178054,5517,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
304,625174,5,5,,103178054,5517,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
305,625175,5,5,,103178054,5517,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
306,625176,1,9,,103178054,5517,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
307,625177,5,5,,103178054,5517,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
308,625178,5,5,,103178054,5517,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
309,625179,1,9,,103178054,5517,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
310,625180,5,5,,103178054,5517,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
311,625181,5,5,,103178054,5517,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
312,625182,5,5,,103178054,5517,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
313,625183,5,5,,103178054,5517,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
314,625184,5,5,,103178054,5517,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
315,625185,5,5,,103178054,5517,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
316,625186,5,5,,103178054,5517,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
317,625187,5,5,,103178054,5517,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
318,625188,1,9,,103178054,5517,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
319,625189,1,7,,103178054,5517,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
320,625190,4,5,,103178054,5517,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
321,625191,4,7,,103178054,5517,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
322,625192,4,7,,103178054,5517,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
323,625193,5,5,,103178054,5517,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
324,625194,4,7,,103178054,5517,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
325,625195,4,7,,103178054,5517,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
326,625196,5,6,,103178054,5517,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
327,625197,3,4,,103178054,5517,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
328,625198,4,7,,103178054,5517,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
329,625199,4,7,,103178054,5517,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
330,625200,4,7,,103178054,5517,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
331,625201,4,7,,103178054,5517,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
332,625202,4,7,,103178054,5517,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
333,625203,4,7,,103178054,5517,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
334,625204,4,7,,103178054,5517,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
335,625205,4,7,,103178054,5517,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
336,625206,4,7,,103178054,5517,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
337,625207,4,7,,103178054,5517,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
338,625208,5,5,,103178054,5517,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
339,625209,4,7,,103178054,5517,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
340,625210,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
341,625211,1,6,,103178054,5517,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
342,625212,3,4,,103178054,5517,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
343,625213,4,7,,103178054,5517,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
344,625214,1,9,,103178054,5517,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
345,625215,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
346,625216,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
347,625217,4,7,,103178054,5517,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
348,625218,4,7,,103178054,5517,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
349,625219,3,4,,103178054,5517,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
350,625220,4,7,,103178054,5517,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
351,625221,4,7,,103178054,5517,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
352,625222,4,7,,103178054,5517,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
353,625223,4,7,,103178054,5517,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
354,625224,3,4,,103178054,5517,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
355,625225,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
356,625226,4,7,,103178054,5517,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
357,625227,4,7,,103178054,5517,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
358,625228,4,7,,103178054,5517,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
359,625229,5,5,,103178054,5517,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
360,625230,1,6,,103178054,5517,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
361,625231,4,7,,103178054,5517,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
362,625232,1,9,,103178054,5517,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
363,625233,4,7,,103178054,5517,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
364,625234,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
365,625235,4,7,,103178054,5517,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
366,625236,5,5,,103178054,5517,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
367,625237,4,7,,103178054,5517,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
368,625238,4,7,,103178054,5517,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
369,625239,4,7,,103178054,5517,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
370,625240,1,9,,103178054,5517,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
371,625241,4,7,,103178054,5517,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
372,625242,4,7,,103178054,5517,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
373,625243,5,5,,103178054,5517,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
374,625244,5,5,,103178054,5517,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
375,625245,5,5,,103178054,5517,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
376,625246,1,9,,103178054,5517,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
377,625247,5,5,,103178054,5517,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
378,625248,5,5,,103178054,5517,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
379,625249,5,5,,103178054,5517,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
380,625250,5,5,,103178054,5517,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
381,625251,5,5,,103178054,5517,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
382,625252,4,7,,103178054,5517,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
383,625253,4,7,,103178054,5517,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
384,625254,4,7,,103178054,5517,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
385,625255,4,7,,103178054,5517,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
386,625256,4,7,,103178054,5517,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
387,625257,4,7,,103178054,5517,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
388,625258,4,7,,103178054,5517,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
389,625259,4,7,,103178054,5517,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
390,625260,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
391,625261,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
392,625262,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
393,625263,4,7,,103178054,5517,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
394,625264,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
395,625265,1,6,,103178054,5517,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
396,625266,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
397,625267,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
398,625268,4,2,,103178054,5517,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
399,625268,4,2,,103178054,5517,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
400,625268,4,2,,103178054,5517,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
401,625268,4,2,,103178054,5517,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
402,625269,4,7,,103178054,5517,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
403,625270,4,7,,103178054,5517,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
404,625271,5,5,,103178054,5517,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
405,625272,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
406,625273,4,6,,103178054,5517,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
407,625274,1,6,,103178054,5517,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
408,625275,3,4,,103178054,5517,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
409,651828,1,2,,92309034,5517,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
410,651965,1,1,,124893342,5517,Inconclusive,2668494.0,,8.9125,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
411,652106,1,1,,124893342,5517,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
412,678909,1,8,,103178054,5517,Unspecified,239938877.0,18671.0,,,"TP_TRANSPORTER: increase in Doxorubicin intracellular accumulation (Doxorubicin: 5 uM, Tosufloxacin: 500 uM) in P388/ADR cells",Other,11906478.0,
413,686978,1,1,,124893342,5517,Active,79154014.0,55775.0,10.0,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
414,686979,1,1,,124893342,5517,Inconclusive,79154014.0,55775.0,28.1838,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
415,720579,2,1,,124893342,5517,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
416,720580,1,1,,124893342,5517,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
417,720641,1,2,,92309034,5517,Active,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
418,720717,1,3,,92309034,5517,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
419,939306,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020423,Other,,
420,939307,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020423,Other,,
421,939308,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020423,Other,,
422,939309,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020423,Other,,
423,939937,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020423,Other,,
424,939938,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020423,Other,,
425,939939,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020423,Other,,
426,939940,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020423,Other,,
427,939941,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020423,Other,,
428,939942,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020423,Other,,
429,939943,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020423,Other,,
430,939944,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020423,Other,,
431,939945,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020423,Other,,
432,939946,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020423,Other,,
433,939947,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020423,Other,,
434,939948,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020423,Other,,
435,939949,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020423,Other,,
436,939950,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020423,Other,,
437,939951,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020423,Other,,
438,939952,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020423,Other,,
439,939953,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020423,Other,,
440,939954,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020423,Other,,
441,939955,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020423,Other,,
442,939956,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020423,Other,,
443,939957,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020423,Other,,
444,939958,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020423,Other,,
445,956244,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020423,Other,,
446,956245,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020423,Other,,
447,956246,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020423,Other,,
448,956247,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020423,Other,,
449,956248,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020423,Other,,
450,956249,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020423,Other,,
451,956250,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020423,Other,,
452,956251,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020423,Other,,
453,956252,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020423,Other,,
454,956253,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020423,Other,,
455,958129,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020423,Other,,
456,958130,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020423,Other,,
457,958131,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020423,Other,,
458,958132,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020423,Other,,
459,958133,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020423,Other,,
460,958134,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020423,Other,,
461,958135,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020423,Other,,
462,958136,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020423,Other,,
463,958711,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020423,Other,,
464,958712,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020423,Other,,
465,958713,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020423,Other,,
466,958714,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020423,Other,,
467,958715,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020423,Other,,
468,958716,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020423,Other,,
469,958717,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020423,Other,,
470,958718,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020423,Other,,
471,958719,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020423,Other,,
472,958720,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020423,Other,,
473,997949,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: R020423,Other,,
474,997950,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R020423",Other,,
475,997951,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: R020423",Other,,
476,998529,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: R020423",Other,,
477,998530,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: R020423",Other,,
478,998531,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: R020423",Other,,
479,998532,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R020423",Other,,
480,998533,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: R020423",Other,,
481,998534,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: R020423",Other,,
482,998535,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: R020423",Other,,
483,998536,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: R020423",Other,,
484,998537,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: R020423,Other,,
485,998538,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: R020423",Other,,
486,998539,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: R020423,Other,,
487,998540,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: R020423",Other,,
488,998541,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: R020423",Other,,
489,998542,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: R020423",Other,,
490,998543,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: R020423",Other,,
491,998544,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: R020423",Other,,
492,998545,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: R020423",Other,,
493,998546,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: R020423",Other,,
494,998547,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: R020423",Other,,
495,1000410,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: R020423",Other,,
496,1000411,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020423",Other,,
497,1000412,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R020423",Other,,
498,1000413,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: R020423",Other,,
499,1000414,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: R020423,Other,,
500,1000415,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: R020423",Other,,
501,1000416,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: R020423",Other,,
502,1000417,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: R020423",Other,,
503,1000418,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: R020423",Other,,
504,1000419,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: R020423",Other,,
505,1000420,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: R020423",Other,,
506,1000421,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: R020423",Other,,
507,1000422,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: R020423",Other,,
508,1000423,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: R020423",Other,,
509,1000424,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: R020423",Other,,
510,1000425,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: R020423",Other,,
511,1000426,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: R020423",Other,,
512,1001006,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: R020423",Other,,
513,1001007,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: R020423,Other,,
514,1001008,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: R020423",Other,,
515,1001009,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: R020423",Other,,
516,1001010,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: R020423",Other,,
517,1001011,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: R020423",Other,,
518,1001012,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: R020423",Other,,
519,1001013,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: R020423",Other,,
520,1001014,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: R020423",Other,,
521,1001015,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: R020423",Other,,
522,1001016,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020423",Other,,
523,1001017,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: R020423",Other,,
524,1001018,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: R020423",Other,,
525,1001019,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: R020423",Other,,
526,1001020,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: R020423,Other,,
527,1001021,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020423",Other,,
528,1001022,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: R020423",Other,,
529,1001023,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: R020423",Other,,
530,1001024,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: R020423",Other,,
531,1001025,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: R020423",Other,,
532,1001026,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: R020423",Other,,
533,1001027,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: R020423",Other,,
534,1001028,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: R020423",Other,,
535,1002894,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: R020423",Other,,
536,1002895,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: R020423",Other,,
537,1002896,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: R020423",Other,,
538,1002897,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: R020423",Other,,
539,1002898,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: R020423",Other,,
540,1002899,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: R020423",Other,,
541,1002900,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R020423",Other,,
542,1002901,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: R020423,Other,,
543,1002902,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: R020423",Other,,
544,1002903,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: R020423",Other,,
545,1002904,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: R020423",Other,,
546,1002905,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: R020423",Other,,
547,1003489,1,3,,103178054,5517,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: R020423,Other,,
548,1003490,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: R020423",Other,,
549,1003491,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: R020423",Other,,
550,1003492,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: R020423",Other,,
551,1003493,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: R020423",Other,,
552,1003494,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: R020423",Other,,
553,1003495,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: R020423",Other,,
554,1003496,1,3,,103178054,5517,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: R020423",Other,,
555,1079931,1,1,,103178054,5517,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
556,1079932,1,1,,103178054,5517,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
557,1079933,1,1,,103178054,5517,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
558,1079934,1,1,,103178054,5517,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
559,1079935,1,1,,103178054,5517,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
560,1079936,1,1,,103178054,5517,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
561,1079937,1,1,,103178054,5517,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
562,1079938,1,1,,103178054,5517,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
563,1079939,1,1,,103178054,5517,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
564,1079940,1,1,,103178054,5517,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
565,1079941,1,1,,103178054,5517,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
566,1079942,1,1,,103178054,5517,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
567,1079943,1,1,,103178054,5517,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
568,1079944,1,1,,103178054,5517,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
569,1079945,1,1,,103178054,5517,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
570,1079946,1,1,,103178054,5517,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
571,1079947,1,1,,103178054,5517,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
572,1079948,1,1,,103178054,5517,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
573,1079949,1,1,,103178054,5517,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
574,1159607,2,1,,312309969,5517,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
575,1224863,1,1,,176484488,5517,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
576,1224905,2,1,,92309034,5517,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
577,1224905,2,1,,92309034,5517,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
578,1259310,1,1,,333473222,5517,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
579,1259325,1,2,,336954808,5517,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
580,1259407,1,1,,363904254,5517,Active,,,,,CCRIS mutagenicity studies,Other,,
581,1259416,1,2,,340080693,5517,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
582,1259421,1,1,,340080693,5517,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
583,1259423,1,2,,354912156,5517,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
